Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis
Aim. To conduct a systematic review and meta-analysis of studies on the effect of starting dose of regorafenib on overall survival (OS) of patients with chemorefractory metastatic colorectal cancer. Materials and methods. We searched for research data in the PubMed. The analysis included all publica...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2019-09-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/33505 |
| _version_ | 1818148677628198912 |
|---|---|
| author | Mikhail Yu Fedyanin Elizaveta M Polyanskaya Alexey A Tryakin Ilia A Pokataev Sergei A Tjulandin |
| author_facet | Mikhail Yu Fedyanin Elizaveta M Polyanskaya Alexey A Tryakin Ilia A Pokataev Sergei A Tjulandin |
| author_sort | Mikhail Yu Fedyanin |
| collection | DOAJ |
| description | Aim. To conduct a systematic review and meta-analysis of studies on the effect of starting dose of regorafenib on overall survival (OS) of patients with chemorefractory metastatic colorectal cancer. Materials and methods. We searched for research data in the PubMed. The analysis included all publications till 08.20.2019 which compared OS depending on the starting dose of regorafenib (160 mg or less) in the 1st course of therapy. Meta-analysis was conducted using Review Manager Ver. 5.3. Results. Two studies demonstrated decreased OS at starting dose of less than 160 mg (A. Adenis et al., 2016: risk ratio - RR 1.26, 95% confidence interval - CI 1.01-1.56; A. Aljubran et al., 2019: RR 2.25, 95% CI 0.93-5.43). Two studies showed an improvement in OS with a starting dose of less than 160 mg in the 1st course (T. Bekaii-Saab et al., 2018: RR 0.72, 95% CI 0.47-1,11; J. Gotfrit et al., 2017: RR 0.46, 95% CI 0.17-1.22). In two other studies, there was no effect of a starting dose of regorafenib on OS (K. Yamaguchi et al., 2019: RR 0.95, 95% CI 0.82-1.1; G. Argiles et al., 2019: RR 0,86, 95% CI 0.65-1.13). The meta-analysis did not reveal the effect of starting dose of the drug on OS: RR 0.97, 95% CI 0.78-1.21; p=0.79; I2=64. Conclusions. Reducing the starting dose of regorafenib in the 1st course does not decrease OS and can be recommended for routine clinical practice. |
| first_indexed | 2024-12-11T12:54:57Z |
| format | Article |
| id | doaj.art-f75a5a6fb3b94deebfa6d014321cb293 |
| institution | Directory Open Access Journal |
| issn | 1815-1434 1815-1442 |
| language | Russian |
| last_indexed | 2024-12-11T12:54:57Z |
| publishDate | 2019-09-01 |
| publisher | IP Habib O.N. |
| record_format | Article |
| series | Современная онкология |
| spelling | doaj.art-f75a5a6fb3b94deebfa6d014321cb2932022-12-22T01:06:36ZrusIP Habib O.N.Современная онкология1815-14341815-14422019-09-01213101510.26442/18151434.2019.3.19065130235Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysisMikhail Yu Fedyanin0Elizaveta M Polyanskaya1Alexey A Tryakin2Ilia A Pokataev3Sergei A Tjulandin4Blokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyAim. To conduct a systematic review and meta-analysis of studies on the effect of starting dose of regorafenib on overall survival (OS) of patients with chemorefractory metastatic colorectal cancer. Materials and methods. We searched for research data in the PubMed. The analysis included all publications till 08.20.2019 which compared OS depending on the starting dose of regorafenib (160 mg or less) in the 1st course of therapy. Meta-analysis was conducted using Review Manager Ver. 5.3. Results. Two studies demonstrated decreased OS at starting dose of less than 160 mg (A. Adenis et al., 2016: risk ratio - RR 1.26, 95% confidence interval - CI 1.01-1.56; A. Aljubran et al., 2019: RR 2.25, 95% CI 0.93-5.43). Two studies showed an improvement in OS with a starting dose of less than 160 mg in the 1st course (T. Bekaii-Saab et al., 2018: RR 0.72, 95% CI 0.47-1,11; J. Gotfrit et al., 2017: RR 0.46, 95% CI 0.17-1.22). In two other studies, there was no effect of a starting dose of regorafenib on OS (K. Yamaguchi et al., 2019: RR 0.95, 95% CI 0.82-1.1; G. Argiles et al., 2019: RR 0,86, 95% CI 0.65-1.13). The meta-analysis did not reveal the effect of starting dose of the drug on OS: RR 0.97, 95% CI 0.78-1.21; p=0.79; I2=64. Conclusions. Reducing the starting dose of regorafenib in the 1st course does not decrease OS and can be recommended for routine clinical practice.https://modernonco.orscience.ru/1815-1434/article/view/33505colorectal cancerregorafenibmeta-analysis |
| spellingShingle | Mikhail Yu Fedyanin Elizaveta M Polyanskaya Alexey A Tryakin Ilia A Pokataev Sergei A Tjulandin Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis Современная онкология colorectal cancer regorafenib meta-analysis |
| title | Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis |
| title_full | Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis |
| title_fullStr | Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis |
| title_full_unstemmed | Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis |
| title_short | Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis |
| title_sort | effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer a systematic review and meta analysis |
| topic | colorectal cancer regorafenib meta-analysis |
| url | https://modernonco.orscience.ru/1815-1434/article/view/33505 |
| work_keys_str_mv | AT mikhailyufedyanin effectofstartingdoseofregorafenibonoverallsurvivalofpatientswithmetastaticcolorectalcancerasystematicreviewandmetaanalysis AT elizavetampolyanskaya effectofstartingdoseofregorafenibonoverallsurvivalofpatientswithmetastaticcolorectalcancerasystematicreviewandmetaanalysis AT alexeyatryakin effectofstartingdoseofregorafenibonoverallsurvivalofpatientswithmetastaticcolorectalcancerasystematicreviewandmetaanalysis AT iliaapokataev effectofstartingdoseofregorafenibonoverallsurvivalofpatientswithmetastaticcolorectalcancerasystematicreviewandmetaanalysis AT sergeiatjulandin effectofstartingdoseofregorafenibonoverallsurvivalofpatientswithmetastaticcolorectalcancerasystematicreviewandmetaanalysis |